Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

901
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
901
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

8.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.2K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

230
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
230
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

528
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
528

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A markedly increased CK-MB relative index suggests a skeletal muscle contribution to re-elevated troponin T in immune checkpoint inhibitor-associated myositis.

Clinical chemistry and laboratory medicine·2026
Same author

Evaluation of correlations between serum and urinary vitamin D metabolites using LC-MS/MS.

Bioscience reports·2026
Same author

Endometriosis-Associated Ovarian Carcinosarcoma Featuring Well-Differentiated Adenocarcinoma and Fetal Rhabdomyoma-Like Mesenchymal Components: An Unusual Case Report-With Molecular Analysis.

Case reports in pathology·2026
Same author

Association between serum lipid-apolipoprotein alterations and soluble syndecan-1 dynamics in sepsis: impact of apolipoprotein E isoforms.

Biochemistry and biophysics reports·2026
Same author

Evaluation of optimal growth conditions for Enterobacterales thymidine-dependent small-colony variants: A pilot study for the development of antimicrobial susceptibility testing.

Journal of microbiological methods·2026
Same author

Impact of angiotensin receptor-neprilysin inhibitor therapy on urinary C-peptide measurements: A potential pitfall in the β-cell function assessment.

Clinica chimica acta; international journal of clinical chemistry·2026

Related Experiment Video

Updated: Dec 4, 2025

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.6K

Highly oxidized low-density lipoprotein does not facilitate platelet aggregation.

Akari Miyazaki1, Takeshi Uehara1, Yoko Usami1

  • 1Department of Laboratory Medicine, Shinshu University Hospital, Matsumoto, Japan.

The Journal of International Medical Research
|October 26, 2020
PubMed
Summary

Oxidized low-density lipoprotein (oxLDL) initially activates platelets but then inhibits their aggregation and beta-thromboglobulin secretion, impacting cardiovascular disease development.

Keywords:
Oxidized low-density lipoproteinaggregometryatherosclerosiscardiovascular diseaseplateletβ-thromboglobulin

More Related Videos

Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research
06:35

Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research

Published on: March 29, 2024

968
Stimulation of Vascular Endothelial Cells Using Neutrophil Extracellular Traps in the Presence of Low-Density Lipoprotein
07:26

Stimulation of Vascular Endothelial Cells Using Neutrophil Extracellular Traps in the Presence of Low-Density Lipoprotein

Published on: August 12, 2025

556

Related Experiment Videos

Last Updated: Dec 4, 2025

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.6K
Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research
06:35

Author Spotlight: Innovative Techniques for ROS Detection and Implications for Platelet Research

Published on: March 29, 2024

968
Stimulation of Vascular Endothelial Cells Using Neutrophil Extracellular Traps in the Presence of Low-Density Lipoprotein
07:26

Stimulation of Vascular Endothelial Cells Using Neutrophil Extracellular Traps in the Presence of Low-Density Lipoprotein

Published on: August 12, 2025

556

Area of Science:

  • Biochemistry
  • Cardiovascular Biology
  • Hematology

Background:

  • Cardiovascular disease (CVD) is a leading cause of mortality worldwide.
  • Platelet aggregation plays a critical role in the pathogenesis of arterial thrombosis and CVD.
  • Oxidized low-density lipoprotein (oxLDL) is implicated in the development of atherosclerosis.

Purpose of the Study:

  • To investigate the effect of oxidized low-density lipoprotein (oxLDL) on platelet aggregation.
  • To determine the role of oxLDL in platelet activation and its contribution to cardiovascular disease.

Main Methods:

  • Platelet aggregation was assessed using light transmittance aggregometry and laser light scattering.
  • Beta-thromboglobulin (β-TG) release from platelets was measured after incubation with LDL and oxLDL.
  • Different concentrations and incubation times were employed to study oxLDL effects.

Main Results:

  • Oxidized low-density lipoprotein (oxLDL) demonstrated a dual effect on platelet aggregation, initially weak activation followed by inhibition.
  • Adenosine diphosphate-induced platelet aggregation was reduced in the presence of oxLDL.
  • Oxidized low-density lipoprotein (oxLDL) transiently increased and then decreased beta-thromboglobulin (β-TG) secretion.

Conclusions:

  • Oxidized low-density lipoprotein (oxLDL) exhibits complex effects on platelet function in vitro.
  • While oxLDL can weakly activate platelets early on, it ultimately inhibits platelet aggregation and beta-thromboglobulin secretion.
  • These findings suggest a nuanced role for oxLDL in platelet-mediated thrombosis and cardiovascular disease.